Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer Recurrence”

13,873 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 13,873 results

Testing effectiveness (Phase 2)Study completedNCT03625323
What this trial is testing

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Who this might be right for
NSCLCHNSCC
Immutep S.A.S. 187
Testing effectiveness (Phase 2)Study completedNCT02311582
What this trial is testing

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Who this might be right for
Malignant Glioma
Washington University School of Medicine 55
Testing effectiveness (Phase 2)Study completedNCT00091182
What this trial is testing

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Who this might be right for
Childhood Central Nervous System Germ Cell TumorChildhood Extragonadal Germ Cell TumorChildhood Hepatoblastoma+23 more
National Cancer Institute (NCI) 180
Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Not applicableNot Yet RecruitingNCT07618546
What this trial is testing

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Who this might be right for
HCC - Hepatocellular Carcinoma
Henan Cancer Hospital 208
Early research (Phase 1)Study completedNCT00085488
What this trial is testing

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Melanoma (Skin)
Dartmouth-Hitchcock Medical Center
Large-scale testing (Phase 3)Ended earlyNCT00312442
What this trial is testing

Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

Who this might be right for
Prostate Cancer
STEBA France 16
Early research (Phase 1)Active Not RecruitingNCT05739942
What this trial is testing

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Who this might be right for
Newly Diagnosed and Recurrent Glioblastoma
Novartis Pharmaceuticals 42
Testing effectiveness (Phase 2)Study completedNCT03561870
What this trial is testing

Olaparib in Recurrent IDH-mutant Glioma

Who this might be right for
Recurrent IDHMutant High Grade Glioma
Hospices Civils de Lyon 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07612254
What this trial is testing

APBI Re-irradiation

Who this might be right for
Breast Cancer Recurrent
Dartmouth-Hitchcock Medical Center 30
Not applicableStudy completedNCT00775866
What this trial is testing

MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy

Who this might be right for
Recurrent Prostate Cancer
University Health Network, Toronto 82
Testing effectiveness (Phase 2)Ended earlyNCT00003496
What this trial is testing

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer Extensive Stage
Burzynski Research Institute 4
Early research (Phase 1)Ended earlyNCT01801046
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

Who this might be right for
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)+24 more
University of Southern California 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04190446
What this trial is testing

Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaOligometastatic Prostate CarcinomaProstate Adenocarcinoma+2 more
Mayo Clinic 84
Not applicableStudy completedNCT00020527
What this trial is testing

Caspofungin Acetate in Treating Children With Fever and Neutropenia

Who this might be right for
Fever, Sweats, and Hot FlashesInfectionKidney Cancer+5 more
National Cancer Institute (NCI)
Not applicableEnded earlyNCT01806961
What this trial is testing

Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.

Who this might be right for
Actinic Keratosis
Spirig Pharma Ltd. 16
Testing effectiveness (Phase 2)Study completedNCT00027742
What this trial is testing

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Intraocular MelanomaMelanoma (Skin)
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00040586
What this trial is testing

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Who this might be right for
Prostatic Neoplasms
BZL Biologics
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Next Page